Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 8, 2021

BMS’ deucravacitinib fails to meet efficacy goals in ulcerative colitis trial

No new safety signals linked to the therapy were observed in the trial with safety profile in line with reported data.

Bristol Myers Squibb (BMS) has reported that its drug, deucravacitinib, failed to meet the primary and secondary efficacy goals of the Phase II LATTICE-UC clinical trial in moderate to severe ulcerative colitis (UC) patients.

An oral, selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib possesses a peculiar mechanism of action.

It specifically acts on TYK2, to hinder interleukin (IL)-23, IL-12 and Type 1 interferon (IFN) signalling.

These are the main cytokines linked to the pathogenesis of various immune-mediated diseases.

The randomised, placebo-controlled, multicentre Phase II trial analysed the safety and efficacy of deucravacitinib in moderate to severe UC patients.

Clinical remission as assessed using the updated Mayo score at week 12 was the trial’s primary goal.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The secondary goals of the trial comprised clinical response evaluated using the modified Mayo score, endoscopic response and histological improvement at week 12.

Findings showed that the safety profile of deucravacitinib was in line with already reported trials in psoriasis and psoriatic arthritis.

Furthermore, no new safety signals linked to the treatment were reported in the trial.

Bristol Myers Squibb chief medical officer Samit Hirawat said: “Deucravacitinib has been shown to be a highly effective, first-in-class, oral, selective TYK2 inhibitor in psoriasis and we have ongoing Phase III trials exploring the potential of deucravacitinib in psoriatic arthritis.

“While we did not achieve proof of concept in this study, we are committed to advancing our deucravacitinib clinical programme in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, as well as in psoriatic arthritis, lupus and other immune-mediated diseases.”

The company will conduct a complete review of the LATTICE-UC data.

BMS is currently analysing an increased dose of deucravacitinib for UC in another Phase II IM011-127 trial.

This randomised, placebo-controlled, multicenter study will evaluate the safety, efficacy and biomarker response of the drug in moderate to severe US participants.

Clinical response and safety and tolerability at week 12 are the primary goals of the trial.

Last month, BMS reported positive three-year data from the CheckMate -743 clinical trial where first-line therapy with Opdivo (nivolumab) plus Yervoy (ipilimumab) offered a lasting survival benefit in unresectable malignant pleural mesothelioma patients, irrespective of histology.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU